Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medtronic’s Renal Denervation System Will Get Parallel Treatment From FDA And CMS

This article was originally published in The Pink Sheet Daily

Executive Summary

The device is one the first, and perhaps the most high profile, to participate in the budding parallel review program, in which CMS can begin considering a national Medicare coverage policy for a new technology as FDA is reviewing its safety and efficacy for regulatory approval.

You may also be interested in...



FDA-CMS Parallel Review Saves Time, Clinical Trial Costs, Participant Says

Exact Sciences, one of the first companies to volunteer for a pilot program launched in 2011 testing FDA-CMS parallel review, says its experience with the process so far is very positive. Agency officials are planning to review experiences with the program to make improvements.

St. Jude Plans Trial To Study Renal Denervation Outcomes

Landmark trial will evaluate if reductions in blood pressure caused by renal denervation translate to clinical improvements in patients with hard-to-treat hypertension.

Boston Scientific Enters Renal Denervation Market Via Vessix Acquisition

Deal gives Boston Scientific access to the V2 radiofrequency energy-based renal denervation catheter system for drug-resistant hypertension.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS075380

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel